Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder
The purpose of this study is determine whether the use of topiramate is effective in the treatment of alcohol dependence (i.e. decreases drinking) in patients with bipolar disorder.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Topiramate
Phase: Phase 4
Ages Eligible For Study:
1. Age 18+ 2. Written informed consent. 3. Meet DSM-IV criteria (by SCID) for alcohol dependence. 4. Meet DSM-IV criteria (by SCID) for bipolar disorder I or II disorder. 5. ? 8 heavy drinking days (defined as ? 5 standard drinks per day for men, ? 4 standard drinks per day for women) in the prior 4 weeks. 6. During the baseline visit, patients must be on a stable dose of accepted maintenance treatment for bipolar disorder for the past 4 weeks. If the subject is on more than one agent, at least one agent must be adequately dosed. 7. Antidepressant treatment is permitted if the dose has been stable for the past 4 weeks.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michael J. Ostacher, MD, MPH